Concepedia

Alfred Alfred Witjes

AA

Statistics

Publications

3

Citations

59

H-Index

3

Active since

2023

Affiliations

Radboud University Nijmegen(Current)

Carolina Urologic Research Center

Icahn School of Medicine at Mount Sinai

Alfred Alfred Witjes is an author at Radboud University Nijmegen specializing in oncology, bladder cancer, and medicine.

Publications per year

2023–2023

3

Publications

3

Phase 3 KEYNOTE-905/EV-303: Perioperative pembrolizumab (pembro) or pembro + enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).

Andrea Necchi, Jens Bedke, Matt D. Galsky et al. · Journal of Clinical Oncology · 2023 · 22 citations

Medicine, Oncology, Perioperative Medicine +12

Extended follow-up results from the CheckMate 274 trial.

Matt D. Galsky, Alfred Alfred Witjes, Jürgen E. Gschwend et al. · Journal of Clinical Oncology · 2023 · 22 citations

Medicine, Oncology, Pharmacotherapy +16

Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select <i>FGFR</i> mutations or fusions: Phase 1 first-in-human study.

Antoni Vilaseca, Daniel Zainfeld, Neal D. Shore et al. · Journal of Clinical Oncology · 2023 · 15 citations

Medicine, Oncology, Pharmacology +14

1–3 of 3